Antipsychotics may confer long term benefits and risks, including cardiovascular disease (CVD) risk. Several studies using routine clinical data have reported associations between antipsychotics and CVD but potential confounding and unclear classification of drug exposure limits their interpretation.
Introduction
Cardiovascular disease (CVD) mortality and morbidity is markedly elevated in people with severe mental illnesses such as schizophrenia, for reasons including smoking, deprivation and health care (Osborn et al. 2007 ). The contribution of antipsychotic medication to CVD risk and CVD mortality has generated scientific, clinical and policy-focused debate. The mechanism might include the cumulative adverse effects of different agents, including weight gain, glucose, ECG abnormalities and lipid levels. A systematic review in 2009 concluded that antipsychotics were associated with increased CVD mortality in schizophrenia (Weinman et al. 2009 ). However contradictory evidence has emerged in the past five years. Large cohort studies have been published using linked national data in Finland (Kiviniemi et al. 2013 , Tiihonen et al. 2009 ), Sweden (Torniainen et al. 2014 , Crump et al. 2014 ) of people with long term or first onset schizophrenia as well as UK studies including all people using antipsychotics in primary care (Murray-Thomas et al. 2013) . These studies have shown varying results, reporting that second generation antipsychotic users are either more or less likely to develop from cardiovascular disease. There has been particular concern regarding olanzapine in terms of cardiovascular risks, including weight gain, and it is one of the most commonly prescribed antipsychotics in the UK and internationally (Weinman et al. 2009 , Marston et al. 2014 ).
Comparing the risk for CVD with individual antipsychotics such as olanzapine is methodologically challenging; it requires large studies with sufficient person years of followup. Most studies addressing these questions use large routinely collected data sources, since bespoke trials and cohort studies of this size and length of follow-up are probably unfeasible. However using routine data bring major challenges. This includes the highly heterogeneous groups of people in the data source, often deriving from quite different time periods. More historical cohorts may have poorer quality information on older exposures, but they often have greater statistical power by virtue of larger numbers of CVD events.
More contemporary cohorts of younger people may provide higher quality data on exposures (such as smoking or drug dose), but will have fewer CVD events. The theoretical pathway by which antipsychotics may predispose to CVD is probably complex and lengthy.
Different agents may affect different parts of this pathway. These effects cannot be differentiated unless we select "purer" cohorts exposed to single antipsychotic agents during follow-up. However in real life clinical setting, from which data are often derived, patients switch between medications, stopping and starting medications for periods of time (Leiberman et al. 2005) . This makes it difficult to establish which agent might be associated with any elevated or decreased risk of CVD mortality. It is also important to carefully select outcomes in research using routine databases. Many studies of antipsychotic outcomes simply combine all causes of mortality however this approach is unlikely to yield meaningful evidence when the mechanisms underlying different diseases and causes of death (such as suicide and CVD) are so varied (Weinman et al. 2009 , De Hert et al. 2010 .
A further challenge with routine data is assessing the role of confounding, when estimating the relationship between different antipsychotics and CVD. To do this we need good quality data on potential confounding factors such as co-morbid physical health, diagnoses, or substance misuse. These variables are not available in many large observational datasets.
We designed a study to compare risk of incident CVD in people prescribed the three most commonly used antipsychotic agents in the UK, olanzapine, risperidone and quetiapine. We aimed to address some of the aforementioned challenges when using routinely available clinical data. We aimed to select groups of people with who only used one of the three most common antipsychotics during their follow-up and to compare their risk of incident CVD.
We assessed whether olanzapine confers greater risk of CVD than other second generation antipsychotics. We used propensity score matching to select three groups of antipsychotic users who were similar in terms of their balance of known confounders.
Methods

Study design
A prospective cohort study using routinely collected data in UK primary care
Setting
We extracted data from The Health Improvement Network (THIN) (THIN, 2015) , a United Kingdom primary care database which derives data from routine administrative and clinical practice. We used data from an established cohort of THIN patients prescribed first and second generation antipsychotics in UK primary care (Marston et al. 2014) . THIN includes longitudinal data from more than 12 million patients with a geographical spread that is generally representative of the UK general population (Blak et al. 2011 ). Staff at general practices enter data using a hierarchical system of Read codes (Chisholm 1990, Dave and Petersen 2009) , for information such as symptoms, signs and diagnoses. THIN has been successfully used for a range of mental health and pharmaco-epidemiological research including work regarding antipsychotics, severe mental illnesses and cardiovascular disease (Marston et al. 2014; Hayes et al. 2016; Osborn et al. 2014 ).
Participants
The cohort included all people aged over 18 with an electronic record of being prescribed olanzapine, risperidone or quetiapine during follow-up, between 1995 and December 2011.
We excluded people with pre-existing cardiovascular disease, heart failure or dementia.
Main exposure
Since we aimed to identify sole users of the most common three antipsychotics, we excluded people who were prescribed additional first or second antipsychotics during follow-up, in addition to their index drug. This derived three groups of people solely receiving 1) olanzapine 2) risperidone or 3) quetiapine.
Follow-up period
Follow up commenced at first prescription of risperidone, olanzapine or quetiapine and ended at death, incident CVD, the patient leaving the practice or December 2011. We excluded those with less than 6 months follow-up data.
Covariates for propensity score matching
In order to balance the observed characteristics of the groups receiving the different antipsychotics, we generated propensity scores for receiving olanzapine, versus either risperidone or quetiapine. We created plots of propensity score distributions to visually compare 1) olanzapine versus risperidone sole users and 2) olanzapine versus quetiapine sole users. We then used propensity score matching to select groups of patients receiving the pairs of drugs of interest. We included people whose propensity scores overlapped using predefined criteria below and we excluded patients for whom we could not find an eligible comparison. We selected patients using 1:1 matching of propensity score, without replacement, but including individuals with tied scores. Calipers for matching pairs of patients were set at 0.2 of a standard deviation of the propensity score as recommended by Austin (2011) for observational studies.
We calculated the propensity scores for each patient using logistic regression. We included a range of relevant variables in the model. These variables were selected by the research team, including epidemiologists, experts in primary care data, academic GPs and psychiatrists. We were deliberately inclusive and made use of any socio-demographic, biometric, diagnostic or co-prescribing variable which might plausibly influence or be related to the choice of olanzapine risperidone quetiapine or which might influence the CVD outcome.
We included the following variables: Mental health diagnoses (category of Severe Mental Illness diagnosis, namely schizophrenia, bipolar disorder or other psychosis (Hardoon et al. 2013 )), ADHD, anxiety, depression, OCD, personality disorder, post-traumatic stress disorder, sleep disorders (Marston et al. 2014); chronic physical illnesses at any time (defined as asthma, atrial fibrillation, chronic kidney disease, chronic obstructive pulmonary disease (COPD), diabetes, hypertension, hypothyroid, learning disability, on the palliative care register); receipt of other main classes of medication at any time (antidepressants, diabetes medication, anti-hypertensive medication at any time, hypnotics, insulin, statin use); socio-demographic factors and health indicators at any time before baseline, using the value closest to baseline where there was more than one measurement. These included age at baseline, sex, Townsend quintile (The Townsend index, a widely used measure of geographical social deprivation; Townsend 1986) , time period when the person entered the cohort, high alcohol intake, illicit drug use, ethnicity, smoking status, number of drug subchapters from the BNF prescribed from taken in the year before baseline, systolic blood pressure, height, weight, blood glucose, HbA1c, HDL cholesterol, total cholesterol); mental health consultations (a record of seeing a psychologist, a psychiatrist, or mental health crisis). These definitions have previously been published (Marston et al. 2014; Osborn et al. 2014 ).
Main outcome
New records of fatal or non-fatal cardiovascular disease, defined as a myocardial infarction, coronary heart disease, angina pectoris, major coronary surgery and revascularisation, cerebrovascular accident (CVA) and transient ischaemic attacks (TIA) (Osborn et al. 2014) .
Analysis
Summary descriptive statistics were calculated for people who were and were not included in the propensity score matched groups, for each pair of antipsychotics namely olanzapine versus risperidone and olanzapine versus quetiapine. We then determined the number of CVD events occurring during follow-up for each group of matched antipsychotic users. We calculated incidence rate ratios for cardiovascular disease comparing sole users of olanzapine against 1) sole users of risperidone and 2) sole users of quetiapine, using Poisson regression. We performed a supplementary analysis to explore the impact of matching on propensity scores by calculating Incident rate ratios for the total, unmatched sample.
Finally we performed an additional, more restricted propensity score analysis, where we only included medical variables which had recorded before baseline and therefore before the first prescription of antipsychotic, in case any of the variables within our propensity score might have resulted directly from the prescription of the antipsychotic.
Analyses were carried out using Stata version 13 (StataCorp 2013).
Results
We identified 18,319 people who were sole users of one of the three antipsychotics of interest, including 5909 sole users of risperidone, 7,797 sole users of olanzapine and 4613 sole users of quetiapine. Figure one is a flow chart of people included and excluded from this sample. The median follow-up period across the three groups of sole users was 2.3 years (IQR 1.2-4.4); giving a total of 57,448 person years. The commonest additional prescriptions in the excluded groups were additional first generation antipsychotics during follow-up (n=7078; 22.3%) and also receiving an additional drug out of the three most common namely olanzapine, risperidone or quetiapine (n=2907; 9.2%). The mean time from GP registration to first prescription of each antipsychotic was risperidone 2.11 years (sd 3.10); olanzapine 2.40 years (sd 3.37) and quetiapine 3.19 years (4.01).
Olanzapine vs. risperidone
The distribution of the propensity scores and the characteristics of olanzapine versus risperidone users before and after matching are shown in figure 2, Tables 1 and 2. The propensity score distributions in figure 2 are very different for olanzapine and risperidone users prior to matching. The total unmatched risperidone group was more likely to be male, fewer were recorded as having white ethnicity, fewer lived in deprived areas of the UK and fewer had one of the SMI diagnoses such as schizophrenia (table 1). However there were more people diagnosed with diabetes mellitus in the risperidone group, mean weight in Kg was higher in the risperidone group and the people receiving olanzapine were more likely to have had contact with secondary mental health services (table 2).
After the propensity score matching, the groups who were users of olanzapine and risperidone were more similar regarding variables such as gender, diagnosis, ethnicity, coprescribing, weight and diabetes. (tables 1 and 2) .
Olanzapine vs. quetiapine
The unmatched groups of sole users of olanzapine and quetiapine were also different in terms of their propensity score distributions (figure 2), as well as the individual variables contributing to the propensity score (tables 1 and 2). People receiving only quetiapine during their follow-up were more likely to be male, white, and less likely to have a SMI diagnosis including schizophrenia, compared to those receiving olanzapine (table 1).
However they were more likely to have a diagnosis of diabetes and to be in receipt of antidiabetic or anti-hypertensive medication (table 2). After the propensity score matching, the two groups were far more similar in terms of their baseline characteristics.
Relative incidence rates of cardiovascular events
Head to head comparisons of individual antipsychotic agents
The propensity score matching exercise resulted in 4557 olanzapine sole users and 4753 risperidone sole users with 15,805 and 16,171 years of follow-up respectively. The numbers developing a CVD event were 100 (2.2%) for olanzapine and 132 (2.8%) for risperidone. The incidence rate ratio (IRR) for CVD in olanzapine compared to risperidone was 0.78 (0.60-1.01) (table 3). In the supplementary analysis using the unmatched sample, the unadjusted IRR suggested that CVD rates were significantly lower in the olanzapine users compared to risperidone users (model 2; table 3), however this association within the unmatched sample disappeared after adjusting for age, sex and deprivation (model 3 , table 3).
The additional propensity score matching exercise, only including variables recorded before baseline, resulted in fewer people being included in each antipsychotic group (supplementary tables 1-2 and supplementary figure). However there was still no difference in CVD incidence between the two olanzapine and risperidone (IRR 1.07; 0.78-1.45) supplementary table 3).
In the olanzapine versus quetiapine analysis, there were 3789 olanzapine sole users, with 10,323 years of follow-up eligible for comparison with the 4133 quetiapine sole users with 10,601 years follow-up. The numbers developing a CVD event were 81 (2.1%) and 82 (2.0%) respectively. After accounting for person years of follow-up, the incidence rate ratio for CVD in olanzapine users (compared to quetiapine users) was 0.96 (0.71-1.31). In the supplementary analysis using the unmatched sample, the unadjusted IRR also showed no significant differences in CVD rates between the olanzapine users and quetiapine users (model 2; table 3). However when this unmatched IRR was adjusted for age, sex and deprivation, the olanzapine users were significantly more likely to develop CVD (IRR 1.52 1.16 to 1.98 ; model 3, table 3).
The additional propensity score matching exercise, again resulted in fewer people being included in each antipsychotic group (supplementary tables 1-2). However there was still no difference in CVD incidence between the olanzapine and quetiapine (IRR 0.90; 0.62-1.30) supplementary table 3).
Discussion
This large study aimed to address methodological criticisms of previous studies reporting the risks of CVD with antipsychotics (De Hert et al. 2010 ). When we included a large number of variables to create propensity scores, and matched by these scores, we found no significant differences in rates of cardiovascular disease when comparing sole users of olanzapine with sole users of either risperidone or quetiapine.
We used routinely collected primary care data and endeavoured to address some of the problems inherent to these types of data. We found evidence that people receiving these three individual drugs differed considerably at baseline, in terms of very important variables such as gender, ethnicity, and key cardiovascular risk factors such as weight and diabetes.
Perhaps surprisingly, those prescribed olanzapine had lower weight and lower rates of diabetes and obesity, which could lead to erroneous results if not accounted for. Through propensity score matching, we identified groups who were similar in terms of these characteristics. We derived sample sizes of three to four thousand people solely prescribed each drug, with between 10 and 15 thousand person years of follow-up for each drug, and did not find different rates of cardiovascular disease. In our study we sought to make our groups as similar as possible in terms of the variables we assessed, however some residual confounding is likely to still be present (Freemantle et al, 2013) . For instance the severity of the diseases for which the drugs are prescribed may be different, as well as the associated level of impairment, which might influence CVD risk.
Our study identified more CVD events for each individual antipsychotic agent than many of the recent antipsychotic mortality cohort studies which have reported that antipsychotics are harmful or beneficial in relation to all-cause mortality, or in terms of suicide and in terms of CVD mortality (Murray Thomas et al. 2013; Kiviniemi et al. 2013) . THIN also offers more information regarding possible confounding variables, compared to studies based on national linked samples such as the large Scandinavian databases. Our work demonstrates the challenges of designing studies to assess long term associations between medications used for long term mental health conditions and events such as CVD.
The methodological strengths of our study include restricting the exposed samples to people who only received one individual antipsychotic of interest during their follow-up, and the propensity score matching to account for known confounders. This allowed head to head comparisons of sole users, which has rarely been done in previous studies; many researchers group antipsychotic drugs by class or simply look at people exposed and unexposed to any antipsychotic. An exception is Crump et al. (2014) , who divided antipsychotic users into subgroups of 'any use' and 'sole use'. However their analysis was also limited by small numbers of CVD deaths in their large Swedish cohort, and they only report all-cause (not CVD) mortality for each individual antipsychotic agent.
Limitations
All routine databases have limitations in terms of missing data on covariates, lack of information regarding prescriptions outside follow-up time, and in our case, lack of data regarding prescriptions in secondary care. However in the UK most people are registered with a general practitioner (Lis and Mann, 1995) and most prescribing for long term conditions is performed by general practitioners (Prah et al. 2007 ) . An exception is clozapine which is mainly prescribed by psychiatric outpatient clinics-so we did not aim to assess CVD risk in people receiving this medication. The selection of sole users is methodologically pure, but in reality many people switch between agents over time (Lieberman et al. 2005) . The effects of switching between different agents and CVD outcomes would be hard to study and are not be addressed by our study design.
Since we did not find associations between the individual antipsychotics of interest and CVD, there was no reason to assess subdivisions of exposure such as high and low doses, length of exposure or any interaction between medications and diagnosis. However these subdivisions would not have been possible given the number of CVD events, and this is a lesson for future research studies-they need to be extremely large to look at dose effects of individual agents or to explore specific subtypes of CVD such as coronary heart disease or stroke. Because our sample are matched on propensity scores, we cannot provide estimates of CVD incidence according to the variables within those propensity scores, such as age or diagnosis.
We recommend that future cohort studies of antipsychotics should carefully assess issues of confounding, using propensity score matching or other applicable methods, but must still recognise that it may be impossible to adjust for unmeasured confounders, such as the clinical reasons why a certain drug may be chosen for certain individuals. For the last two decades, clinicians and patients have been warned of the potential for weight gain, particularly with olanzapine (de Hert et al, 2010) . Our results suggest that people receiving this drug in real life are less likely to be overweight or have diabetes, which perhaps indicates a deliberate avoidance of the drug in people at risk of these conditions. However, this means that any studies of longer term outcomes must control for the baseline differences in people receiving these agents, or results regarding risks and benefits of antipsychotics may be biased and inaccurate.
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